2023 HRS/APHRS/LAHRS Guideline on Cardiac Physiologic Pacing for the Avoidance and Mitigation of Heart Failure

Authors, Journal, Affiliations, Type, DOI

Overview

This guideline defines cardiac physiologic pacing (CPP) as any pacing intended to restore or preserve ventricular synchrony, an umbrella covering coronary-sinus or epicardial cardiac resynchronization therapy (CRT) and conduction system pacing (CSP) — His bundle pacing (HBP) and left bundle branch area pacing (LBBAP). It is the first document to place all three strategies on one recommendation scale, and its central finding is a hierarchy of evidence rather than of physiology: CRT rests on multiple randomised trials with mortality benefit, whereas the CSP evidence is overwhelmingly observational, so CSP is offered as an alternative at COR 2a or 2b and never at COR 1 for a heart-failure indication. The guideline delivers 73 recommendations across indications, pre-procedure evaluation, implantation, follow-up and congenital/pediatric populations, with a mean consensus of 97.3% and 32 recommendations at 100%. Its most consequential new content is a quantified definition of "substantial" right ventricular pacing (20%–40%), COR 2b clearance for LBBAP in normal left ventricular ejection fraction, and COR 1 status for CRT in women at QRS 120–149 ms.

Keywords

Guideline · Cardiac resynchronization therapy · Conduction system pacing · His bundle pacing · Left bundle branch area pacing · Cardiac physiologic pacing · Pacing-induced cardiomyopathy · Heart failure

Key Takeaways

Top 10 Take-Home Messages

  1. CPP is any pacing that restores or preserves ventricular synchrony, achieved either by engaging the intrinsic conduction system (CSP: HBP or LBBAP) or by CRT, most often biventricular pacing through a coronary sinus branch.
  2. The evidence for CRT is substantially stronger than for CSP. Multiple randomised trials show CRT reduces symptoms, heart failure hospitalisation, improves left ventricular function and increases survival; most CSP data are observational and long-term lead survival data are lacking.
  3. "Response" has no consensus definition and may mean improved mortality or hospitalisation, improved clinical parameters, stabilised ventricular function, or simply prevention of progression.
  4. Periodic assessment of ventricular function is recommended for patients requiring substantial right ventricular pacing, or with chronic left bundle branch block (LBBB), to detect pacing- or dyssynchrony-induced cardiomyopathy.
  5. Patients expected to need substantial ventricular pacing may be considered for CPP to reduce the risk of pacing-induced cardiomyopathy.
  6. Patients with left ventricular ejection fraction (LVEF) 35%–50% expected to need less than substantial pacing may not benefit sizeably from CPP — conventional right ventricular lead placement with pacing minimisation, CSP and CRT in the presence of LBBB are all acceptable.
  7. LBBAP receives new recommendations at COR 2b for patients with normal LVEF who need a pacing device.
  8. CRT remains COR 1 for heart failure with LVEF ≤35%, LBBB, QRS ≥150 ms and NYHA class II–IV on guideline-directed medical therapy; CSP is COR 2a only when effective CRT cannot be achieved, and CRT is now COR 1 for select characteristics (eg, female sex) at QRS 120–149 ms.
  9. New CPP recommendations cover non-LBBB with LVEF ≤35% at both QRS <150 and ≥150 ms, at COR 2b.
  10. Electrocardiographic demonstration of biventricular capture (CRT) or conduction system capture (CSP) is essential during implantation and at follow-up.

Definitions

Term Definition
LBBB QRS ≥120 ms with a broad notched or slurred R wave in leads I, aVL, V5 and V6, per the 2009 AHA/ACCF/HRS ECG standardisation statement
CPP Any cardiac pacing intended to restore or preserve ventricular synchrony, by CSP or CRT
CSP Recruitment of the intrinsic conduction system by HBP or LBBAP
HBP Direct stimulation of the His bundle; selective (His only) or nonselective (His plus local septal myocardium)
LBBAP Ventricular pacing intended to engage all or part of the left bundle fascicular system; selective LBB pacing, nonselective LBBAP, or deep septal pacing with no direct left bundle recruitment
CRT Left ventricular stimulation timed to right ventricular sensing or pacing, most commonly biventricular pacing; for this guideline CRT means biventricular or LV pacing, not CSP
Substantial RVP Documented or anticipated right ventricular pacing of ≥20%–40%; less than substantial means <20%–40%

Detection of Dyssynchrony-Induced Cardiomyopathy

Recommendation COR LOE
Periodic assessment of ventricular function in patients with substantial right ventricular pacing that cannot be minimised by programming, to detect pacing-induced cardiomyopathy 1 B-NR
Periodic assessment of ventricular function in patients with chronic LBBB 2a B-NR

Pacemaker Indications — Substantial Ventricular Pacing

Applies to patients with a bradycardia pacing indication, not those with a pre-existing heart-failure indication.

Recommendation COR LOE
LVEF 36%–50% with anticipated substantial ventricular pacing: CPP is reasonable to reduce pacing-induced cardiomyopathy 2a B-R (CRT); B-NR (HBP, LBBAP)
Normal LVEF with anticipated substantial ventricular pacing: CPP may be reasonable to reduce pacing-induced cardiomyopathy 2b B-NR
Ventricular pacing–dependent patient undergoing HBP pacemaker implantation: an additional backup lead may be reasonable 2b C-LD

Pacemaker Indications — Less Than Substantial Ventricular Pacing

Recommendation COR LOE
LVEF >35% with anticipated less than substantial pacing: traditional RV lead placement with minimisation of right ventricular pacing is reasonable 2a B-R
LVEF 36%–50%: a CSP lead with HBP or LBBAP may be considered as an alternative to an RV lead 2b C-LD
LVEF 36%–50% with LBBB: CPP may be considered to improve symptoms and LVEF 2b C-LD
Normal LVEF: an LBBAP lead may be considered as an alternative to an RV lead 2b C-LD
Normal LVEF with anticipated less than substantial pacing: CRT with biventricular pacing is not indicated 3: No Benefit B-R

At the Time of Cardiac Surgery

Recommendation COR LOE
Patients undergoing cardiac surgery who will likely require future CRT: intraoperative permanent epicardial LV lead can be useful 2a B-R
Patients who will likely require substantial ventricular pacing: intraoperative permanent epicardial LV lead may be considered to reduce pacing-induced cardiomyopathy 2b C-EO

Heart Failure with LBBB, QRS ≥150 ms

Recommendation COR LOE
LVEF ≤35%, sinus rhythm, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CRT with biventricular pacing is indicated to improve symptoms and reduce morbidity and mortality 1 A
Same population: CSP with HBP with LBBB correction or LBBAP is reasonable if effective CRT cannot be achieved with biventricular pacing on anatomical or functional grounds 2a C-LD
LVEF ≤30%, LBBB, QRS ≥150 ms, NYHA I on GDMT: CRT with biventricular pacing may be considered 2b B-R
LVEF 36%–50%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CPP may be considered to maintain or improve LVEF 2b C-LD
LVEF ≤35%, LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CSP with HBP or LBBAP may be considered as an alternative to CRT 2b C-LD

Heart Failure with LBBB, QRS 120–149 ms

Recommendation COR LOE
Select characteristics (eg, female sex), LVEF ≤35%, LBBB, QRS 120–149 ms, NYHA II–IV on GDMT: CRT is recommended to reduce mortality and heart failure events and improve LVEF 1 A
LVEF ≤35%, LBBB, QRS 120–149 ms, NYHA II–IV on GDMT: CRT is reasonable 2a B-R

Heart Failure with Non-LBBB

Recommendation COR LOE
LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA III or ambulatory IV on GDMT: CRT can be useful to improve functional class, structure and LVEF 2a A
LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA II on GDMT: CPP may be considered 2b B-R (CRT); C-LD (HBP, LBBAP)
LVEF ≤35%, non-LBBB, QRS ≥150 ms, NYHA II–IV on GDMT: CSP may be reasonable if effective CRT cannot be achieved 2b C-LD
LVEF ≤35%, non-LBBB, QRS 120–149 ms, NYHA III–IV on GDMT: usefulness of CPP is not well established 2b B-NR (CRT); C-LD (HBP, LBBAP)
LVEF ≤35%, NYHA II–IV on GDMT, QRS <120 ms: CRT is not recommended 3: No Benefit B-R
LVEF ≤35%, non-LBBB, QRS <150 ms, NYHA I–II on GDMT: CRT is not recommended 3: No Benefit B-R

Pacing-Induced Cardiomyopathy with High-Burden Right Ventricular Pacing

Recommendation COR LOE
Declining LV function or worsening heart failure attributed to substantial ventricular pacing: CRT with biventricular pacing is recommended 1 B-NR
Same population: revision of the device to a CSP system can be beneficial 2a B-NR

Pacing in Atrial Fibrillation

Recommendation COR LOE
AF undergoing atrioventricular junction (AVJ) ablation with LVEF ≤50%: CRT is reasonable to improve heart failure hospitalisation, reverse remodelling, quality of life, exercise capacity, LVEF and potentially mortality 2a B-R
AF otherwise meeting CRT eligibility: CRT can be beneficial 2a B-NR
AF undergoing AVJ ablation: HBP with or without a backup ventricular lead may be reasonable 2b C-LD
AVJ ablation: it may be reasonable to implant an LBBAP lead 2b C-LD
High burden of ventricular pacing: HBP or LBBAP may be reasonable to decrease the risk of AF 2b C-LD

Survival Less Than One Year

Combination CRT (LV Lead plus HBP or LBBAP)

Pre-Procedure Evaluation

Recommendation COR LOE
12-lead ECG to evaluate rhythm, rate, atrioventricular conduction, and QRS duration and morphology to determine the type of CPP 1 A
Pre-procedural echocardiographic screening for LVEF 1 A (CRT); C-EO (HBP, LBBAP)
Imaging (echocardiography, cardiac MRI or CT) to target LV lead placement in CRT 2b B-R
Pre-procedural echocardiographic assessment of ventricular dyssynchrony to predict CRT outcome 3: No Benefit A
Shared decision-making covering the evidence base, goals of care, preferences, battery longevity, future lead management and end-of-life considerations 1 C-EO

Implant Technique — CRT with Biventricular Pacing

Recommendation COR LOE
Quadripolar LV lead 1 B-R
Lead positioning and programming to deliver the narrowest QRS duration 2a B-NR
LV lead placement allowing a non-apical position 2a C-LD
Targeting sites of late ventricular activation 2b C-LD

Implant Technique — Conduction System Pacing

Recommendation COR LOE
12-lead ECG during implantation to assess conduction system capture 1 C-EO
Demonstration of conduction system capture thresholds (including bundle branch block correction) and myocardial capture thresholds at implant 1 C-EO
Assessment of His bundle or left bundle current of injury using appropriate filter settings 2a C-LD

Intraprocedural Crossovers

Recommendation COR LOE
Coronary sinus LV lead placement unsuccessful or suboptimal: crossover to CSP with HBP or LBBAP is reasonable 2a C-LD
Initial approach unsuccessful or suboptimal: crossover to surgical epicardial CRT might be reasonable 2b C-LD

Follow-Up

Recommendation COR LOE
Follow-up echocardiogram within 3–12 months after implantation in HFrEF 1 B-NR (CRT); C-EO (HBP, LBBAP)
Remote monitoring 1 B-NR
Multidisciplinary management with heart failure and device clinics 2a B-NR (CRT); C-EO (HBP, LBBAP)
Continuation of guideline-directed medical therapy in heart failure with improved ejection fraction 2a C-LD
Routine use of thoracic impedance alone to manage congestive heart failure 3: No Benefit B-R

Generator Replacement and Troubleshooting

Recommendation COR LOE
Heart failure with improved ejection fraction: continuation of CRT at elective replacement 1 C-LD
Patient thought to have benefited from CRT (improvement, stabilisation or partial reversal of decline): continuation of CRT at elective replacement 1 C-EO
CRT-D at elective replacement: decide replacement versus revision to CRT-P by individualised risk–benefit and shared decision-making 1 B-NR
High lead pacing threshold contributing to rapid battery drain: a new lead may be considered at generator replacement 2b C-EO
Unfavourable response to CRT: continued optimisation of medical and device therapy 1 C-LD
Unfavourable response: posteroanterior and lateral chest X-ray to assess LV lead position 1 C-LD
Unfavourable response with suboptimal LV pacing percentage: ablation or pharmacological suppression of frequent PVCs, or better rhythm/rate control of AF 2a C-LD
Suboptimal response to CRT: CSP or surgical epicardial lead implantation can be useful when other approaches have failed or are not feasible 2a C-LD (HBP, LBBAP); B-NR (surgical epicardial)

Congenital Heart Disease

Recommendation COR LOE
CHD, systemic LV, on GDMT, LVEF <45%, ventricular dyssynchrony (QRS z-score ≥3 or ventricular pacing ≥40%): CRT is reasonable to reduce mortality or transplant need 2a C-LD
CHD, systemic single ventricle requiring pacing: apical pacing is reasonable in preference to non-apical 2a C-LD
CHD, systemic single ventricle with symptomatic heart failure: CRT with multisite ventricular pacing may be considered 2b C-LD
CHD, systemic RV with symptomatic heart failure associated with ventricular electrical delay or substantial pacing: CRT may be considered 2b C-LD
CHD, subpulmonary RV dysfunction with RBBB: CRT with fusion-based pacing may be considered 2b C-LD
Congenitally corrected transposition of the great arteries with AV block and no anatomic repair: CSP with HBP or LBBAP may be considered 2b C-LD

Pediatric Patients Without Congenital Heart Disease

Recommendation COR LOE
Complete AV block, pre-existing ventricular pacing and symptomatic heart failure on GDMT: CRT is reasonable 2a C-LD
Complete AV block with clinical heart failure on GDMT: CPP may be considered 2b C-LD
Pacemaker implantation for AV block: target an RV mid-septal, inflow or outflow tract transvenous site, or apical LV epicardial pacing, in preference to RV apical endocardial or epicardial pacing 2a C-LD

Identified Evidence Gaps

Limitations of the document

Key Concepts Mentioned

Key Entities Mentioned

Wiki Pages Updated